Health
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 COG1201 SHIMMER study (NCT05225415) of zervimesine (CT1812) in dementia with Lewy bodies (DLB) at the AD/PD™ 2026 Alzheimer's & Parkinson's Diseases Conference. The conference is being conducted March 17-21, 2026 in Copenhagen, Denmark. The analysis f
About this update from Cognition Therapeutics, Inc.
[{"type":"image","alt":"Cognition Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Cognition Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3G97CJjBroOGRUYevL.t.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22","width":250,"height":70}},"lazy":false},{"type":"text","content":"PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 COG1201 SHIMMER study (NCT05225415) of zervimesine (CT1812) in dementia with Lewy bodies (DLB) at the AD/PD™ 2026 Alzheimer's & Parkinson's Diseases Conference. The conference is being conducted March 17-21, 2026 in Copenhagen, Denmark. The analysis focuses on Zervimesine’s treatment effects on the behavioral and psychiatric symptoms most commonly associated with DLB.","length":631,"tagName":"p"},{"type":"text","content":"“In the Phase 2 ‘SHIMMER’ study, we saw a treatment effect across neuropsychiatric, cognitive, motor, and global function domains with zervimesine treatment compared to placebo,” explained Anthony Caggiano, MD, PhD, Cognition’s CMO. “This effect was particularly robust against DLB’s behavioral and psychiatric symptoms, which have been identified as important to patients and care partners. We’re presenting a breakdown of zervimesine’s effect relative to placebo on the components of the neuropsychiatric index (NPI), which was employed in the Phase 2 study.”","length":561,"tagName":"p"},{"type":"text","content":"Zervimesine treatment resulted in an 86% slowing of decline on NPI-12 vs placebo in that Phase 2 study. This slowing of decline reflects zervimesine’s unique disease-modifying mechanism of action. Acute treatments for psychosis may improve one symptom but will not delay progression of the disease. Based on our clinical data, we believe zervimesine has the potential to slow DLB progression and reduce the progression of its associated neuropsychiatric symptoms.","length":463,"tagName":"p"},{"type":"text","content":"I...